Drug Trial Radar · NCT03218995
Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping
Last checked: Nov 20, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Aug 16, 2017
Primary completion
Mar 10, 2021
Study completion Mar 10, 2021
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 months, up to 48 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and PK of once-weekly IV infusions of eteplirsen in approximately 12 male participants, ages 6 months to 48 months (inclusive), who have genotypically confirmed DMD with a deletion mutation amenable to exon 51 skipping.
Conditions
- Duchenne Muscular Dystrophy
Interventions
EteplirsenDrug
Infusion for intravenous use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation From Study DrugTime frame: Baseline up to Week 100
- Number of Participants With at Least 1 Potentially Clinically Significant Clinical Safety Laboratory AbnormalityTime frame: Baseline up to Week 100
- Number of Participants With at Least 1 Markedly Abnormal Vital SignTime frame: Baseline up to Week 100
- Abnormal Changes From Baseline or Worsening of Physical Examination FindingsTime frame: Baseline up to Week 100
- Number of Participants With at Least 1 Markedly Abnormal Electrocardiogram (ECG) and Echocardiogram (ECHO)Time frame: Weeks 8, 12, 24, 36, 48, 60, 72, 84, 96
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Universitair ziekenhuis Gent
Ghent, Belgium
Armand-Trousseau Hospital
Paris, France
Site Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
UCL Great Ormond Street Institute of Child Health
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.